Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex.
1. The previously described complex behaviour of the CCKB/gastrin receptor antagonist, L-365,260, in radioligand binding assays could be explained by a variable population of two binding sites. We have investigated whether other CCKB/gastrin receptor ligands (PD134,308, PD140,376, YM022 and JB93182) can distinguish between these sites. 2. In the mouse cortex assay, Hill slopes were not different from unity and the ligand pKI values did not differ when either [125I]-BH-CCK-8S or [3H]-PD140,376 was used as label as expected for a single site (G2). 3. In the rat cortex, where previous analysis of replicate (n=48) L-365,260 data indicated the presence of two CCKB/gastrin sites (G1 and G2), the competition data for PD134,308, PD140,376, YM022 and JB93182 could be explained by a homogeneous population of CCKB/gastrin sites because the Hill slope estimates were not significantly different from unity. However, the estimated affinity values for JB93182 and YM022 were significantly higher and that for PD134,308 was significantly lower than those obtained in the mouse cortex when the same radioligand was used. In view of our previous data obtained with L-365,260, the rat cortex data were also interpreted using a two-site model. In this analysis, SR27897 expressed approximately 9 fold, PD134,308 approximately 13 fold and PD140,376 approximately 11 fold selectivity for the G2 site. In contrast, JB93182 expressed approximately 23 fold and YM022 approximately 4 fold selectivity for the G1 site. If the two-site interpretation of the data is valid then, because of its reverse selectivity to L-365,260, JB93182 has been identified as a compound which if radiolabelled could provide a test of this receptor subdivision.
Harper
E A
EA
James Black Foundation, Dulwich, London, England.
Griffin
E P
EP
Shankley
N P
NP
Black
J W
JW
D000818:Animals; D001569:Benzodiazepines / Q000378:metabolism / Q000494:pharmacology; D001570:Benzodiazepinones / Q000378:metabolism* / Q000494:pharmacology; D001665:Binding Sites; D001667:Binding, Competitive / Q000187:drug effects; D001952:Bridged-Ring Compounds / Q000378:metabolism / Q000494:pharmacology; D002540:Cerebral Cortex / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D004151:Dipeptides / Q000378:metabolism / Q000494:pharmacology; D006168:Guinea Pigs; D006727:Hormone Antagonists / Q000378:metabolism / Q000494:pharmacology; D007210:Indoleacetic Acids / Q000378:metabolism / Q000494:pharmacology; D007211:Indoles / Q000378:metabolism / Q000494:pharmacology; D007457:Iodine Radioisotopes; D008297:Male; D008536:Meglumine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D051379:Mice; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism; D010671:Phenylurea Compounds / Q000378:metabolism* / Q000494:pharmacology; D011869:Radioligand Assay; D051381:Rats; D017208:Rats, Wistar; D043886:Receptor, Cholecystokinin A; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000819:agonists / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012844:Sincalide / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D013388:Succinimides / Q000378:metabolism / Q000494:pharmacology; D013844:Thiazoles / Q000378:metabolism / Q000494:pharmacology; D014316:Tritium
D001570:Benzodiazepinones; C044758:Bolton Hunter-cholecystokinin octapeptide; D001952:Bridged-Ring Compounds; D004151:Dipeptides; D006727:Hormone Antagonists; D007210:Indoleacetic Acids; D007211:Indoles; D007457:Iodine Radioisotopes; C109753:JB93182; D010671:Phenylurea Compounds; D043886:Receptor, Cholecystokinin A; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; D013388:Succinimides; D013844:Thiazoles; D014316:Tritium; D001569:Benzodiazepines; C065599:PD 134308; C080460:SR 27897; C087260:YM 022; C080765:PD 140376; C058121:L 365260; D008536:Meglumine; D012844:Sincalide